The client wanted to understand how hematologists and HemOncs approach the diagnosis of diffuse large B-cell lymphoma (DLBCL), including the diagnostic methods they rely on and the challenges they encounter in current standard-of-care practices. The objective was to build a clearer picture of prevailing diagnostic practices and use these insights to inform broader business strategy.
Borderless Access engaged with 100 hematologists and HemOncs across the EU and USA through focused research discussions. The study examined how physicians diagnose DLBCL, the tests they commonly rely on including imaging and tissue or lymph node biopsies and their use of cell-of-origin (COO) classification to better understand the type of lymphoma.
The research gave the client a clearer view of prevalent diagnostic methods and physician practice in DLBCL. These insights provided a stronger basis for understanding the current diagnostic landscape and informing business strategy and operations.






© 2026 Borderless Access Pvt Ltd. All Rights Reserved.